The European Union’s vaccination campaign has suffered another setback. As confirmed by the British-Swedish drugmaker AstraZeneca, the European Union will soon receive less of the vaccine than originally planned. The company attributed the problems to the European supply chain.
At the end of the coming week, the European Union is expected to approve the vaccine from AstraZeneca, which requires less cooling than the vaccine from Biotech / Pfizer, already used in the EU. The Mens-based company and US partners are currently struggling with a distribution bottleneck in the European Union.
[Wenn Sie alle aktuellen Nachrichten live auf Ihr Handy haben wollen, empfehlen wir Ihnen unsere runderneuerte App, die Sie hier für Apple- und Android-Geräte herunterladen können.]
On Friday evening, EU circles were told that AstraZeneca would probably deliver 60 percent less of the vaccine in the first quarter than originally planned. Accordingly, it was originally planned that AstraZeneca would distribute approximately 80 million vaccine doses to 27 EU countries in the first and second quarter. It should now be only 31 million vaccine doses in the first quarter.
Vaccination has been introduced in the UK since the beginning of the month
The company’s vaccine, headquartered in Cambridge, UK, has been vaccinated in the UK since the beginning of the month. According to the company, deliveries will continue in the UK despite production difficulties affecting the European Union. The reason for this lies in the separate supply chains for the UK and the EU.
Crisis in EU Steering Committee meeting on Monday
EU Health Commissioner Stella Kyrakaides announced on Twitter that the EU Commission and European Member States expressed “deep dissatisfaction” with the drastic cuts in delivery at a meeting of the European Union’s steering committee on immunization strategy on Friday. Another meeting of the EU Steering Committee is planned with representatives of AstraZeneca for the following Monday.
Lauterbach criticizes EU purchasing strategy
SPD health expert Karl Lauterbach criticized the EU’s vaccination strategy. “Vaccine production in Europe develops too late and too slowly,” Lauterbeck told Tegesipagel, “America has more vaccines than vaccines, it’s the other way around in Europe,” he told the EU. What to do with The procurement strategy, which we certainly should not repeat, “said Luterbach. Now, according to the SPD politician, it is a matter of looking ahead.” More than this, the vaccine will not prevent lockdown against dangerous variants. If the lockdown works perfectly and is very successful, it will give us more time for vaccination, ”he said.